RNTX — Rein Therapeutics Inc.

Summary of Aileron Therapeutics Q3 2019 Earnings Call

1. Key Financial Results and Metrics

• R&D Expenses: $4.5 million, up from $4.3 million in Q3 2018, primarily due to increased clinical development costs for ALRN-6924.
• General and Administrative Expenses: $3.4 million, compared to $3.2 million in Q3 2018.
• Net Loss: $7.7 million, or $0.28 per share, compared to a net loss of $7.4 million, or $0.50 per share in the same period last year.
• Cash Position: $24.6 million as of September 30, 2019, up from $20.7 million at the end of 2018, expected to fund operations into Q4 2020.

2. Strategic Updates and Business Highlights

• Leadership Changes: Significant changes in the executive team were made to strengthen the company, including the appointment of a new Chief Medical Officer and other key roles.
• R&D Focus: The company is concentrating on two clinical programs for ALRN-6924:
  • Combination Therapy: ALRN-6924 with Pfizer's IBRANCE (palbociclib) for MDM2-amplified cancers, with positive interim results presented at ESMO.
  • Myelopreservation Program: Evaluating ALRN-6924 as a myelopreservation agent to reduce chemotherapy-related toxicities in patients with p53 mutant cancers. A Phase 1b/2 trial is underway.
• Clinical Results: The combination therapy showed a median progression-free survival of 4.4 months in a subgroup of patients, with a 73% progression-free survival rate at 12 weeks.

3. Forward Guidance and Outlook

• Upcoming Milestones: Final data from the Phase 2a trial of the combination therapy and dose optimization data for the myelopreservation program are expected in Q2 2020.
• Expansion Plans: Plans to enroll additional cohorts for the myelopreservation program are set for Q2 2020, contingent on resource availability.

4. Bad News, Challenges, or Points of Concern

• No Complete Responses: While the combination therapy showed promising results, there were no observed partial or complete responses in the interim analysis.
• Competitive Landscape: G1 Therapeutics has made advancements in myelopreservation, which could pose a competitive threat. Aileron’s strategy must effectively differentiate its approach to succeed in this area.
• Regulatory Uncertainty: The pathway to FDA approval for the myelopreservation indication remains uncertain, especially in light of competitors' progress.

5. Notable Q&A Insights

• Myelopreservation Study Timeline: Questions about timelines for FDA approaches were addressed, indicating that Aileron is closely monitoring competitor developments while planning its regulatory strategy.
• Differentiation of ALRN-6924: The company emphasized that ALRN-6924 is a peptide drug with a unique safety profile compared to small molecule MDM2 inhibitors, which could provide a competitive edge.
• Focus on Biomarkers: The myelopreservation program will utilize a biomarker-driven strategy for patient selection and efficacy assessments, which is seen as a key differentiator from competitors.

Overall, Aileron Therapeutics is positioned to advance its clinical programs with promising data but faces challenges in a competitive landscape and must navigate regulatory pathways carefully.